Inhibition of ristocetin-induced patient PRP aggregation. Amplitude of aggregation of PRP by (A) 0.3 and (B) 0.5 mg/mL ristocetin in the absence (“none”) and in the presence of 10 μg/mL of the inhibitory anti-vWF monoclonal antibody AJvW-2, of 14 μg/mL of the inhibitory anti-GPIb monoclonal antibody G19H10, and of 10 μg/mL of the anti-FcγRII receptor monoclonal antibody IV.3.